Home
About
Overview
Sharing Data
ORCID
Help
History (20)
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors.
Differences in hypothalamic type 2 deiodinase ubiquitination explain localized sensitivity to thyroxine.
PHM Award for Educational Achievement
Regulation of innate and adaptive immunity by the commensal microbiota.
The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy.
See All 20 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy.
The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy. Expert Opin Drug Saf. 2019 Dec; 18(12):1127-1132.
View in:
PubMed
subject areas
Animals
Antiemetics
Antineoplastic Agents
Humans
Nausea
Neurokinin-1 Receptor Antagonists
Quality of Life
Spiro Compounds
Vomiting
authors with profiles
Rudolph Navari